ACA
IOVA icon

Atlas Capital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Atlas Capital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-950
Closed -$9.1K – 925
2022
Q3 		$9.1K Buy
+950
New +$11K ﹤0.01% 724
2022
Q2 		– Sell
-950
Closed -$15.8K – 996
2022
Q1 		$15.8K Hold
950
– – ﹤0.01% 658
2021
Q4 		$18.1K Hold
950
– – ﹤0.01% 650
2021
Q3 		$23.4K Hold
950
– – ﹤0.01% 622
2021
Q2 		$24.7K Buy
950
+300
+46% +$7.8K ﹤0.01% 627
2021
Q1 		$20.6K Hold
650
– – ﹤0.01% 601
2020
Q4 		$30.2K Buy
+650
New +$25.8K 0.01% 511
2020
Q3 		– Sell
-650
Closed -$17.8K – 435
2020
Q2 		$17.8K Buy
+650
New +$21.4K ﹤0.01% 561

Other funds holding IOVA

State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Atlas Capital Advisors's IOVA Position: Q4 2022 in Review

Atlas Capital Advisors sold out of Iovance Biotherapeutics (IOVA) in Q4 2022, closing a stake of 950 shares — an estimated $9.1K sold.

Atlas Capital Advisors first reported a position in IOVA in Q2 2020 and held it in 8 quarters. The position peaked at $30.2K in Q4 2020. 218 funds tracked by Wall St. Rank hold IOVA as of Q4 2022.

  • Atlas Capital Advisors reported no remaining Iovance Biotherapeutics position as of Q4 2022 after selling out during the quarter.
  • Atlas Capital Advisors sold 950 Iovance Biotherapeutics shares in Q4 2022, an estimated $9.1K.
  • Atlas Capital Advisors first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 8 quarters.
  • Atlas Capital Advisors's Iovance Biotherapeutics position peaked at $30.2K in Q4 2020.
  • 218 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2022.

Based on Atlas Capital Advisors's 13F filing for Q4 2022, filed 15 Feb 2023.